Updated Jul 16, 2026
Farzan Nima has filed 2 SEC Form 4 filings across 1 company in the last 90 days — selling. Lifetime open-market sales: $28K.
Farzan Nima is identified in SEC filings as an insider associated with Keros Therapeutics, Inc. as of June 5, 2026. The publicly available SEC context does not specify his exact title or role within the company, and no broader biographical details are readily available from major reference sources as of the date provided.
| Role | Insider |
|---|---|
| Notability | 15/100 |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-06-08 | KROS | Keros Therapeutics, Inc. | S — Open-market sale | 2.6K | $10.73 | $28K |
| 2026-06-05 | KROS | Keros Therapeutics, Inc. | A — Grant or award | 7.1K | $0.00 |
Farzan Nima is identified in SEC filings as an insider associated with Keros Therapeutics, Inc. as of June 5, 2026. The publicly available SEC context does not specify his exact title or role within the company, and no broader biographical details are readily available from major reference sources as of the date provided.…
2 primary Form 4 filings in the last 90 days, covering 1 company.
Recorded transactions: 0 open-market purchases () and 1 open-market sales ($28K) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Farzan Nima profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.